Colleen Hadigan, M.D., M.P.H.

Senior Clinician

Office of the Chief Medical Officer

NIH Clinical Center

Clinical Director

NIH Clinical Center

Building 10, Room 6-2551
10 Center Drive
Bethesda, MD 20892


Research Topics

Dr. Hadigan's academic medical career has been primarily centered in clinical research with much of the focus on the long-term and metabolic complications of HIV and its therapies in both children and adults. In 2006, she came to the National Institutes of Health as a member of the Laboratory of Immunoregulation of the National Institute of Allergy and Infectious Disease (NIAID). In addition to her active research and mentoring, Dr. Hadigan served as the Deputy Manager of the NIAID Outpatient HIV and Infectious Diseases Research Clinic for over 10 years. In October of 2021 she became the Chief Medical Officer and Clinical Director for the NIH Clinical Center. She is board certified in Pediatrics and Pediatric GI and Hepatology and remains clinically active as the Pediatric GI and Hepatology consultant for the NIH Clinical Center.


Dr. Hadigan received her medical degree from the Johns Hopkins School of Medicine and subsequently completed her residency in Pediatrics at Boston Children’s Hospital followed by a fellowship in Pediatric Gastroenterology and Hepatology in the Harvard Combined Program for Pediatric Gastroenterology, Hepatology and Nutrition at Boston Children’s Hospital and Massachusetts General Hospital. She also received her MPH at the Harvard School of Public Health.

Selected Publications

  1. Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830.
  2. George JM, Kuriakose SS, Monroe A, Hou Q, Byrne M, Pau AK, Masur H, Hadigan C, Castel AD, Horberg MA, District of Columbia (D.C.) Cohort Executive Committee. Utilization of Direct Oral Anticoagulants in People Living with Human Immunodeficiency Virus: Observational Data from the District of Columbia Cohort. Clin Infect Dis. 2020;71(10):e604-e613.
  3. Fourman LT, Stanley TL, Billingsley JM, Sui SJH, Feldpausch MN, Boutin A, Zheng I, McClure CM, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Chung RT, Grinspoon SK. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Sci Rep. 2021;11(1):10485.
  4. Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16).
  5. Thiara DK, Liu CY, Raman F, Mangat S, Purdy JB, Duarte HA, Schmidt N, Hur J, Sibley CT, Bluemke DA, Hadigan C. Abnormal Myocardial Function Is Related to Myocardial Steatosis and Diffuse Myocardial Fibrosis in HIV-Infected Adults. J Infect Dis. 2015;212(10):1544-51.

Related Scientific Focus Areas

This page was last updated on Wednesday, June 19, 2024